Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: betty moyers who wrote (13031)	8/11/1998 11:51:00 AM
From: DaiS	Read Replies (1) \| Respond to of 23519

Betty, Thanks for your update on earnings situation yesterday. Regarding scripts: As we know, we cannot work out from the number of new and refill the number of regular muse users because this depends how often men get written prescriptions and exactly what is written on these prescriptions. However I suspect one fairly accurate piece of information can be got from the refill data. Assuming that it is regular users that get the refills then the ratio of refills at different times should equal the ratio of regular users at those times. Thus pre-viagra there were 5000 refills and now there are just over 2000. This suggests to me that Viagra has removed 60% of the muse regulars - not so bad when you consider that muse users may well have been first in line to try viagra. I cannot remember if this was posted before, biz.yahoo.com Provides another possible explanation for absence of coat-tail effect benefitting muse. I still believe that there is pressure on doctors not to prescribe muse. The new viagra labelling for Europe suggests this also. DaiS But it provides explanation